kw-2478
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00457782)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Heat shock protein HSP 90-alphaINHIBITOR
HSP90AA1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC.Cl- Mol. weight
- 611.13 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4300557 ↗
- ChEMBLCHEMBL4297298 ↗
Also known as
- kw-2478
- kw-2478
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01063907 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2010 | Gleneagles CRC, IQVIA, Kyowa Hakko Kirin |
| NCT00457782 | Phase 1 | Apr 1, 2007 | Barts & The London NHS Trust, Kyowa Hakko Kirin |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyowa Hakko Kirin | For profit | 2 | 2 | 2 | 2007 |
| Barts & The London NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Gleneagles CRC | Academic/Hospital | 1 | 0 | 1 | 2010 |
| IQVIA | For profit | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1